BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NovaCardia, Inc. Appoints Joseph L. Turner To Its Board Of Directors


2/6/2007 12:11:24 PM

SAN DIEGO, Feb. 6 /PRNewswire/ -- NovaCardia, a pharmaceutical company developing small molecule drugs for the treatment of cardiovascular diseases, announced today the appointment of Joseph L. Turner to the company's Board of Directors. Mr. Turner brings over 25 years of financial management experience in the pharmaceutical industry to the board of NovaCardia.

"Joe has played an integral role in the success of both privately held and publicly traded companies, having raised millions of dollars to support biopharmaceutical innovations and grown the companies he's worked with," said Randall E. Woods, President and CEO of NovaCardia. "We look forward to his counsel as the company achieves important company milestones this year, including the initiation of pivotal Phase III trials for KW-3902 for the treatment of congestive heart failure."

Until its sale to Gilead in November 2006, Mr. Turner was Senior Vice President of Finance and Administration and Chief Financial Officer at Myogen, a therapeutics company focused on cardiovascular disease. Prior to Myogen, he was at biopharmaceutical company Centaur Pharmaceuticals, where he served as Vice President, Finance and Chief Financial Officer. Before Centaur, Mr. Turner was Vice President, Finance and Chief Financial Officer of Cortech, Inc. and before that spent 12 years with Eli Lilly and Company, where he held a variety of financial management positions both within the United States and abroad.

About NovaCardia

NovaCardia is a privately held product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing novel, clinical-stage drug candidates. For more information, visit www.novacardia.com.

NovaCardia

CONTACT: Brian Farmer, Director of Corporate Development of NovaCardia,+1-858-509-0455, bfarmer@NovaCardia.com; or Media & Investor Relations, KimRichards of Porter Novelli Life Sciences, +1-619-849-5377,krichards@pnlifesciences.com, for NovaCardia



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES